Uridine triphosphate (UTP) induces profibrotic responses in cardiac fibroblasts by activation of P2Y2 receptors

Journal of Molecular and Cellular Cardiology

Volumn 49, Issue 3, 2010, Pages 362-369

  Braun, Oscar Ö ^a   Lu, David ^a   Aroonsakool, Nakon ^a   Insel, Paul A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ATP; Cardiac fibroblasts; P2Y receptors; PAI 1; Purinergic signaling; UTP

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; ALPHA SMOOTH MUSCLE ACTIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN KINASE C; PURINERGIC P2Y2 RECEPTOR; URIDINE TRIPHOSPHATE;

ANIMAL CELL; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; FIBROBLAST; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; MALE; NONHUMAN; NUCLEIC ACID ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

MUS; RATTUS;

EID: 77955272897     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2010.05.001     Document Type: Article

References (49)

1. Espira L., Czubryt M.P. Emerging concepts in cardiac matrix biology. Can. J. Physiol. Pharmacol. 2009, 87:996-1008.
2. Jessup M., Abraham W.T., Casey D.E., et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009, 119:1977-2016.
3. Souders C.A., Bowers S.L., Baudino T.A. Cardiac fibroblast: the renaissance cell. Circ. Res. 2009, 105:1164-1176.
4. Khan R., Sheppard R. Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology 2006, 118:10-24.
5. van den Borne S.W., Diez J., Blankesteijn W.M., Verjans J., Hofstra L., Narula J. Myocardial remodeling after infarction: the role of myofibroblasts. Nat. Rev. Cardiol. 2010, 7:30-37.
6. Camelliti P., Borg T.K., Kohl P. Structural and functional characterisation of cardiac fibroblasts. Cardiovasc. Res. 2005, 65:40-51.
7. Salazar N.C., Chen J., Rockman H.A. Cardiac GPCRs: GPCR signaling in healthy and failing hearts. Biochim. Biophys. Acta 2007, 1768:1006-1018.
8. Tang C.M., Insel P.A. GPCR expression in the heart; "new" receptors in myocytes and fibroblasts. Trends Cardiovasc. Med. 2004, 14:94-99.
9. Swaney J.S., Patel H.H., Yokoyama U., et al. Adenylyl cyclase activity and function are decreased in rat cardiac fibroblasts after myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 2007, 293:H3216-20.
10. Yokoyama U., Patel H.H., Lai N.C., Aroonsakool N., Roth D.M., Insel P.A. The cyclic AMP effector Epac integrates pro- and anti-fibrotic signals. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:6386-6391.
11. Erlinge D., Burnstock G. P2 receptors in cardiovascular regulation and disease. Purinergic Signal 2008, 4:1-20.
12. Abbracchio M.P., Burnstock G., Boeynaems J.M., et al. International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol. Rev. 2006, 58:281-341.
13. Balogh J., Wihlborg A.K., Isackson H., et al. Phospholipase C and cAMP-dependent positive inotropic effects of ATP in mouse cardiomyocytes via P2Y11-like receptors. J. Mol. Cell. Cardiol. 2005, 39:223-230.
14. Morris J.B., Pham T.M., Kenney B., Sheppard K.E., Woodcock E.A. UTP transactivates epidermal growth factor receptors and promotes cardiomyocyte hypertrophy despite inhibiting transcription of the hypertrophic marker gene, atrial natriuretic peptide. J. Biol. Chem. 2004, 279:8740-8746.
15. Nishida M., Sato Y., Uemura A., et al. P2Y6 receptor-Galpha12/13 signalling in cardiomyocytes triggers pressure overload-induced cardiac fibrosis. EMBO J. 2008, 27:3104-3115.
16. Pham T.M., Morris J.B., Arthur J.F., Post G.R., Brown J.H., Woodcock E.A. UTP but not ATP causes hypertrophic growth in neonatal rat cardiomyocytes. J. Mol. Cell. Cardiol. 2003, 35:287-292.
17. Wihlborg A.K., Balogh J., Wang L., et al. Positive inotropic effects by uridine triphosphate (UTP) and uridine diphosphate (UDP) via P2Y2 and P2Y6 receptors on cardiomyocytes and release of UTP in man during myocardial infarction. Circ. Res. 2006, 98:970-976.
18. Swaney J.S., Roth D.M., Olson E.R., Naugle J.E., Meszaros J.G., Insel P.A. Inhibition of cardiac myofibroblast formation and collagen synthesis by activation and overexpression of adenylyl cyclase. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:437-442.
19. Lugo-Garcia L., Filhol R., Lajoix A.D., Gross R., Petit P., Vignon J. Expression of purinergic P2Y receptor subtypes by INS-1 insulinoma beta-cells: a molecular and binding characterization. Eur. J. Pharmacol. 2007, 568:54-60.
20. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001, 29:e45.
21. Erlinge D., Yoo H., Edvinsson L., Reis D.J., Wahlestedt C. Mitogenic effects of ATP on vascular smooth muscle cells vs. other growth factors and sympathetic cotransmitters. Am. J. Physiol. 1993, 265:H1089-97.
22. Takeshita K., Hayashi M., Iino S., et al. Increased expression of plasminogen activator inhibitor-1 in cardiomyocytes contributes to cardiac fibrosis after myocardial infarction. Am. J. Pathol. 2004, 164:449-456.
23. Weinberg E.O., Shimpo M., Hurwitz S., Tominaga S., Rouleau J.L., Lee R.T. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003, 107:721-726.
24. Lorenz K., Schmitt J.P., Schmitteckert E.M., Lohse M.J. A new type of ERK1/2 autophosphorylation causes cardiac hypertrophy. Nat. Med. 2009, 15:75-83.
25. Cohn J.N., Ferrari R., Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J. Am. Coll. Cardiol. 2000, 35:569-582.
26. Regard J.B., Sato I.T., Coughlin S.R. Anatomical profiling of G protein-coupled receptor expression. Cell 2008, 135:561-571.
27. Talasila A., Germack R., Dickenson J.M. Characterization of P2Y receptor subtypes functionally expressed on neonatal rat cardiac myofibroblasts. Br. J. Pharmacol. 2009, 158:339-353.
28. Wee S., Peart J.N., Headrick J.P. P2 purinoceptor-mediated cardioprotection in ischemic-reperfused mouse heart. J. Pharmacol. Exp. Ther. 2007, 323:861-867.
29. Yitzhaki S., Shainberg A., Cheporko Y., et al. Uridine-5'-triphosphate (UTP) reduces infarct size and improves rat heart function after myocardial infarct. Biochem. Pharmacol. 2006, 72:949-955.
30. Zheng J.S., O'Neill L., Long X., et al. Stimulation of P2Y receptors activates c-fos gene expression and inhibits DNA synthesis in cultured cardiac fibroblasts. Cardiovasc. Res. 1998, 37:718-728.
31. Meszaros J.G., Gonzalez A.M., Endo-Mochizuki Y., Villegas S., Villarreal F., Brunton L.L. Identification of G protein-coupled signaling pathways in cardiac fibroblasts: cross talk between G(q) and G(s). Am. J. Physiol. Cell Physiol. 2000, 278:C154-62.
32. Kakkar R., Lee R.T. Intramyocardial fibroblast myocyte communication. Circ. Res. 2010, 106:47-57.
33. Wildman S.S., Unwin R.J., King B.F. Extended pharmacological profiles of rat P2Y2 and rat P2Y4 receptors and their sensitivity to extracellular H+and Zn2+ ions. Br. J. Pharmacol. 2003, 140:1177-1186.
34. Bouchie J.L., Chen H.C., Carney R., Bagot J.C., Wilden P.A., Feener E.P. P2Y receptor regulation of PAI-1 expression in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 2000, 20:866-873.
35. Klawitter S., Hofmann L.P., Pfeilschifter J., Huwiler A. Extracellular nucleotides induce migration of renal mesangial cells by upregulating sphingosine kinase-1 expression and activity. Br. J. Pharmacol. 2007, 150:271-280.
36. Solini A., Iacobini C., Ricci C., et al. Purinergic modulation of mesangial extracellular matrix production: role in diabetic and other glomerular diseases. Kidney Int. 2005, 67:875-885.
37. Friedman D.J., Rennke H.G., Csizmadia E., Enjyoji K., Robson S.C. The vascular ectonucleotidase ENTPD1 is a novel renoprotective factor in diabetic nephropathy. Diabetes 2007, 56:2371-2379.
38. Dranoff J.A., Ogawa M., Kruglov E.A., et al. Expression of P2Y nucleotide receptors and ectonucleotidases in quiescent and activated rat hepatic stellate cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2004, 287:G417-24.
39. Gerasimovskaya E.V., Ahmad S., White C.W., Jones P.L., Carpenter T.C., Stenmark K.R. Extracellular ATP is an autocrine/paracrine regulator of hypoxia-induced adventitial fibroblast growth. Signaling through extracellular signal-regulated kinase-1/2 and the Egr-1 transcription factor. J. Biol. Chem. 2002, 277:44638-44650.
40. Loskutoff D.J., Edgington T.S. An inhibitor of plasminogen activator in rabbit endothelial cells. J. Biol. Chem. 1981, 256:4142-4145.
41. Eddy A.A., Fogo A.B. Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J. Am. Soc. Nephrol. 2006, 17:2999-3012.
42. Fogo A.B. Renal fibrosis: not just PAI-1 in the sky. J. Clin. Invest. 2003, 112:326-328.
43. Rerolle J.P., Hertig A., Nguyen G., Sraer J.D., Rondeau E.P. Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis. Kidney Int. 2000, 58:1841-1850.
44. Arteel G.E. New role of plasminogen activator inhibitor-1 in alcohol-induced liver injury. J. Gastroenterol. Hepatol. 2008, 23(Suppl 1):S54-9.
45. Nicholas S.B., Aguiniga E., Ren Y., et al. Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy. Kidney Int. 2005, 67:1297-1307.
46. Sobel B.E., Lee Y.H., Pratley R.E., Schneider D.J. Increased plasminogen activator inhibitor type-1 (PAI-1) in the heart as a function of age. Life Sci. 2006, 79:1600-1605.
47. Sobel B.E., Schneider D.J., Lee Y.H., Pratley R.E. Insulin resistance increases PAI-1 in the heart. Biochem. Biophys. Res. Commun. 2006, 346:102-107.
48. Collet J.P., Montalescot G., Vicaut E., et al. Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality. Circulation 2003, 108:391-394.
49. Wiman B., Andersson T., Hallqvist J., Reuterwall C., Ahlbom A., deFaire U. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study. Arterioscler. Thromb. Vasc. Biol. 2000, 20:2019-2023.